SLATE-ASSET-MANAGEMENT
22.7.2022 08:02:07 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired a majority stake in amperio GmbH (“amperio”), a specialist planner and operator of electric vehicle (“EV”) charging infrastructure in Germany.
Amperio is a leading planner and operator of EV charging stations in the highly-fragmented EV charging market in Germany. Since 2012, amperio has been supporting companies, cities, and communities in developing tailored charging concepts, installing charging stations, and providing backend management services for charging stations. To date, amperio has installed over 1,800 intelligent charging points. Amperio maintains, operates, and executes the billing for over 300 of these charging points on behalf of its customers.
As part of the transaction, Slate created Slate Mobility GmbH & Co. KG (“Slate Mobility”), an entity that will finance and own EV charging equipment for Slate and potential third parties and receive management services from amperio. Slate’s portfolio of over 225 grocery properties across Germany and deep network of relationships with tenants focused on environmental sustainability will create a pipeline of opportunities to accelerate amperio’s growth.
Amperio, together with Move About Groups subsidiary mobileeee GmbH (“mobileeee”) and the City of Ludwigshafen in Germany, are implementing a project for station-based public e-carsharing. The project includes the build-up of 27 stations with mobileeee charging infrastructure as well as publicly accessible charging infrastructure. The City Ludwigshafen initiated this concept with the aim of reducing local emissions in the City and its districts.
“To achieve the German government’s target of having at least 15 million electric cars on the roads by 2030 will require significant investment in EV charging points throughout the country,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Amperio is offering a unique, customizable national product to help meet this demand, backed by a team with a proven track record of experience developing charging infrastructure for cities, communities, and businesses. We are excited to partner with amperio to enhance the sustainability infrastructure of our own properties and improve access to efficient charging points all across Germany.”
“Our partnership with Slate presents an exciting opportunity to scale our business and provide seamless and sustainable mobility solutions that are so urgently needed to protect the climate,” added Oliver P. Kaul, Managing Director of amperio. “Our environment has given us the assignment to create zero-emission mobility. Slate has offered us its properties and the funding to accelerate that mission, which amperio embarked on 10 years ago. Together, we strive to achieve our goal of making clean EV charging technology and services widely available.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. Slate’s most recent impact infrastructure investment was a commitment to Eider VF Limited, a UK-based vertical farming business sustainably growing leafy produce to be sold to the UK mass market.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities.
Visit slateam.com to learn more.
About amperio
amperio GmbH is a specialist planner for charging infrastructure based in Cologne. Since 2012, amperio has been supporting companies, cities and municipalities in developing individual charging concepts, installing charging stations and billing charging processes. In doing so, amperio relies on a holistic service that leaves no customer wishes unfulfilled. This includes location analysis, profitability analysis, business model analysis, technical consulting, backend service (monitoring and billing), the operation of charging points, and energy management and subsidy consulting. In addition, amperio offers two charging infrastructure concepts developed in-house with its CHARGE2GO and Mitarbeiter-Strom products. The company has already installed over 1,800 charging points for customers such as Globus, DKB, Groupe PSA, the city of Düren, Volvo, the city of Bad Ems and the MNT Group.
amperio GmbH is part of Slate Asset Management, a global alternative investment platform, which holds a majority stake in amperio GmbH.
Visit amperio.eu to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005973/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
